Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study)
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index; 19 of the 22 sources its claims cite were checked for support.
Abstract
Background: The use of technologies in the health field has progressively increased. Within the context of a broader project funded by the Italian Ministry of Health (TELEMECHRON study), a randomised controlled trial (RCT) has been conducted in the Autonomous Province of Trento on type 2 diabetes individuals with an untargeted glycated haemoglobin (HbA1c) level. Methods: The overall aim was to evaluate the impact of the “TreC Diabete” digital platform, including a smartphone application (app) and a dashboard. This open-label, parallel-group, 1:1 allocation ratio RCT in which the intervention group used the app for data entry, symptoms questionnaire, communication with healthcare staff and medication recording, while the control group received standard care. The primary endpoint was change in HbA1c levels at 12 months between groups. Results: Between December 2022 and August 2023, 103 participants were enrolled (51 intervention; 52 control), with a median age of 67 years old, time from diabetes diagnosis to enrolment 13 years, and 72% male. At 12 months, the median change in HbA1c levels did not differ significantly between groups. Regarding app usage, data entries decreased significantly from the first quarter to the second quarter but subsequently stabilised (p = 0.001). System usability (from 42 responders in the intervention group) had a median score of 95 (range: 0–100), indicating a high level of satisfaction with the platform. Discussion: The study faced several challenges, including platform technical issues, service interruption, data entry anomalies and difficulties in participant recruitment. Study generalisability may be limited by the sample’s demographics, as the trial predominantly included younger male individuals with a specific HbA1c level. Conclusion: The study highlighted key factors for future implementations, including understanding technology benefits, addressing adoption barriers, and providing education and support to both patients and healthcare providers.
Overview
CoChat Summary
TL;DR
In this open-label RCT, the “TreC Diabete” digital platform did not improve 12-month HbA1c change compared with standard care in adults with Type 2 diabetes and non-target HbA1c. Both groups improved glycaemia, while app usage declined early and then stabilised, and usability was rated highly by responders.
Key findings
- Among 103 participants (51 intervention; 52 control), median HbA1c change at 12 months was -6 mmol/mol (IQR -12 to -4) in the intervention group vs -7 mmol/mol (IQR -14 to 0) in the control group, with no significant between-group difference (p > 0.9); both groups decreased significantly from baseline (p < 0.001).
- Glycaemic target achievement (HbA1c < 53 mmol/mol) was 51% in the intervention group vs 42% in the control group (p = 0.4), and secondary clinical outcomes such as weight, LDL cholesterol, non-HDL cholesterol, and blood pressure showed no significant between-group differences.
- App data entries decreased significantly from the first to second quarter and then stabilised (median T1: 150, IQR 52–444; T2: 84, IQR 37–423; T3: 68, IQR 19–449; T4: 66, IQR 9–413; p = 0.001).
- System usability, assessed in 42 intervention-group responders, had a median SUS score of 95 (IQR 78–99), indicating high satisfaction.
Methods
- Open-label, parallel-group, superiority RCT with 1:1 allocation; participants were adults aged 18–85 with HbA1c between 53 and 108 mmol/mol, recruited from outpatient diabetes centres in the Autonomous Province of Trento between December 2022 and August 2023.
- The intervention group used the “TreC Diabete” app for data entry, symptoms questionnaire, communication with healthcare staff, and medication recording, while the control group received standard care.
- The primary endpoint was change in HbA1c at 12 months; analysis followed intention-to-treat with multiple imputation by chained equations when feasible, plus sensitivity, per-protocol, and as-treated analyses.
Limitations
- The paper states technical and operational problems including outdated WebView/app startup issues, complex profile creation, two service interruptions (2 and 12 days), data entry anomalies, recruitment difficulties, smaller-than-planned sample (103 of 120), missing data, low event numbers for secondary outcomes, possible dilution of intervention effect from control-group interactions, and telephone data collection more frequent than planned.
- The paper states generalisability limits: the sample was slightly younger (median 67 vs 70 years in the provincial T2DM population), predominantly male (71.8% vs 56.4%), and restricted to participants with HbA1c 53–108 mmol/mol, while over 50% of the provincial diabetic population had HbA1c below 53 mmol/mol.
- Evident from the text: the open-label design meant participants, clinicians, and data collectors were aware of allocation, and the app-engagement threshold of ≥6 recorded entries per month was arbitrarily defined.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
14 Valid · 0 Not valid · 1 Not checked · 101 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, the meta-analysis conducted by Lee and colleagues including 16 RCTs (participants = 6,204) and focusing on older adults with diabetes, showed several improvements in glycaemic outcomes with a pooled mean HbA1c decreased of -0.24% (95% CI -0.44 to -0.05) (33).”
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Discussion > Comparison with other studies
What the sources say
- Supportedcites [33] Lee, 2023, Effects of mobile health interventions on health-related outcomes in older adults with type 2 diabetes: A systematic review and meta-analysis, J. Diabetes. source
The Results (Study flow) report 16 included RCTs with 3,257 intervention and 2,947 control participants, totaling 6,204. The Results (Glycemic outcomes) report a pooled HbA1c reduction of −0.24% (95% CI −0.44 to −0.05) versus usual care, based on eight studies; they also report improved postprandial glucose. (LLM, conf=0.94)
plainstates a causen = 6,204- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Telemedicine, used as the sole approach to T2DM treatment, is less effective than combined use with an in-person visit or in-person visit alone for glycaemic control, especially in those patients with a worse metabolic control and a complex treatment (36).”
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Discussion > Comparison with other studies
What the sources say
- Partly supportedcites [36] Zupa, 2023, Patterns of telemedicine use and glycemic outcomes of endocrinology care for patients with type 2 diabetes, JAMA Netw. Open sourceExperimental — accuracy not yet measured
The Results (Glycemic Outcomes by Care Modality; Subgroup Analysis: Baseline HbA1c of 8% or Higher) report less HbA1c improvement with telemedicine-only endocrinology care than with in-person or mixed follow-up, including among patients with higher baseline HbA1c. The Discussion says patients using insulin or with HbA1c above goal may not be well served by telemedicine alone. But this retrospective study establishes an association in endocrinology care, not that telemedicine is inherently less effective as a T2DM treatment approach; it also found no significant HbA1c change at 24 months across the full care-modality groups. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Among reviews concerned with diabetes and mHealth system, a meta-analysis study by de Souza Ferreira and colleagues, including 17 trials on diabetes highlighted the effectiveness of mobile apps for monitoring diabetes and hypertension, showing a 0.39% (95% CI 0.24 to 0.54) reduction in HbA1c compared to traditional care (32).”
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Discussion > Comparison with other studies
What the sources say
- Supportedcites [32] De Souza Ferreira, 2023, The effectiveness of mobile application for monitoring diabetes mellitus and hypertension in the adult and elderly population: Systematic review and meta-analysis, BMC Health Serv. Res source
The Results (Meta-analysis) state that 17 studies compared mobile applications for reducing HbA1c in diabetes; the analysis was not performed for hypertension. The Results (Glycated hemoglobin) report a 0.39% reduction (95% CI 0.24–0.54) versus usual care, matching the attributed finding. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An internal analysis using secondary data from the PAT population and The Johns Hopkins Adjusted Clinical Group System (The Johns Hopkins ACG® System) version 11.2 (29) revealed that the Telemechron study sample was slightly younger (median age 67) than the T2DM PAT population (median age 70).”
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Discussion > Generalisability
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 12 months post-randomization, the change in median HbA1c levels did not differ significantly between the two groups.”
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Discussion > Main results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 116 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 45
- Probably not a substantial claim. 47
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Discussion > Main results
“System usability, as assessed by 42 participants in the intervention group out of 52, using the SUS questionnaire”
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Results
“the final number of participants included in the study was 103, with 51 in the intervention group and 52 in the control group.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Results > Outcomes
“The percentage of participants whose HbA1c values fell below the threshold of 53 mmol/mol did not differ significantly between the groups (IG: 52% vs CG 42%, p = 0.4)”
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Results > Outcomes
“| HbA1c target | 0 (0%) | 0 (0%) | – | 26 (51%) | 22 (42%) | 0.4 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Discussion > Main results
“Similarly, secondary outcomes also showed no statistically or clinically significant differences between the two groups.”
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Results > Outcomes
“| IPAQ (Mets) | 3810 (1050, 7080) | 1548 (380, 3248) | 0.001 | 1890 (585-4545) | 1740 (653, 4275) | 0.8 | -470 (-2980, 492) | 283 (-571,1249) | 0.022 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“94 participants were included: 44 in the intervention group and 52 in the control group.”
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Results > Number analysed
Reported 94 · recomputed 96
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Results > Baseline characteristics
“with a glycated haemoglobin of 62 mmol/mol (IQR: 58 to 68 mmol/mol).”
§ Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study) > Results > Baseline characteristics
“| HbA1c, mmol/mol | 60 (57, 68) | 63 (59, 70) | 62 (58, 70) |”
1 more finding
Create a free account to see every finding of this check.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Morisky, 2008, Predictive validity of a medication adherence measure in an outpatient setting, J. Clin. Hypertens. Greenwich Conn, 10, 10.1111/j.1751-7176.2008.07572.x”
Cited work 10.1111/j.1751-7176.2008.07572.x · retracted 2023-08-18 · notice 10.1111/jch.14718 · this paper published 2025-06-10
Citations
Cites
1 retracted
Retracted: Predictive Validity of a Medication Adherence Measure in an Outpatient Setting
Morisky, D. E., Ang, A., Krousel‐Wood, M., & Ward, H. J. (2008) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.07572.x · Cited by 2,877
RetractedWARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
SF-36 health survey: Manual and interpretation guide
Ware, J. (2003) · Medical Entomology and Zoology · Cited by 11,424
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Hagströmer, M., Oja, P., & Sjöström, M. (2006) · Public Health Nutrition · doi:10.1079/phn2005898 · Cited by 1,958
The System Usability Scale: Past, Present, and Future
Lewis, J. R. (2018) · International Journal of Human–Computer Interaction · doi:10.1080/10447318.2018.1455307 · Cited by 1,958
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.004 · Cited by 1,858
Hlatky, M. A., Boineau, R. E., Higginbotham, M. B., Lee, K. L., Mark, D. B., Califf, R. M., Cobb, F. R., & Pryor, D. B. (1989) · The American Journal of Cardiology · doi:10.1016/0002-9149(89)90496-7 · Cited by 1,736
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D., Coca, A., De Simone, G., Dominiczak, A., et al. (2018) · Blood Pressure · doi:10.1080/08037051.2018.1527177 · Cited by 710
Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control
Bress, A. P., Bellows, B. K., King, J. B., Hess, R., Beddhu, S., Zhang, Z., Berlowitz, D. R., Conroy, M. B., Fine, L., Oparil, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmsa1616035 · Cited by 284
Research works printed but not linked: 6
- 2016, Global report on diabetes
- 2024, R: A language and environment for statistical computing
- 2018, The johns hopkins ACG
- 2019, Qualità di cura in base al genere nel DM2
- 2014, World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, J. Am. Coll. Dent., 81, 10.1111/1753-0407.13346 · DOI · Paper page
- 2015, Guideline, ICH Harmonised. “Integrated addendum to ICH E6 (R1): guideline for good clinical practice E6 (R2), Curr. Step, 2, 1, 10.7759/cureus.51791 · doi:10.7759/cureus.51791 · Paper page
Cited by
Ito, H., Hashimoto, S., & KATSUNO, T. (2025) · Emergent Materials · doi:10.1007/s42247-025-01252-z · Cited by 2
Ferrara, F., & Berardinis, F. D. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02398-5
Metadata
- Authors
- Giovanazzi, A., Gios, L., Gentilini, M. A., Mastellaro, M., Bartolotta, P., Nicolussi Giacomaz, L., Eccher, C., & Inchiostro, S.
- Affiliations
- Provincia Autonoma di Trento (IT)
- Fondazione Bruno Kessler (IT)
- Corresponding author
- Inchiostro, Sandro
- Venue
- Frontiers in Clinical Diabetes and Healthcare
- Publisher
- Frontiers Media SA
- Published
- 2025-06-10
- Volume
- 6
- Pages
- 1589548-1589548
- ISSN
- 2673-6616 (ISSN-L)
- PMC
- PMC12186056
- OpenAlex
- W4411187109
- Semantic Scholar
- 8f50c302b4ed6147d83dddff0dc6bc6202b19aec
- Cited by
- 2
- References
- 33
- Citations by year
- 2026: 1 · 2025: 1
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Clinical Diabetes and Healthcare (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fondazione Bruno Kessler
- Topics
- Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, digital health, mobile application, HbA1c, diabetes self-management, patient-reported outcomes, system usability, technology adoption barriers, remote patient monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study). https://app.cochat.ai/papers/10.3389/fcdhc.2025.1589548
- The paper
- Giovanazzi, A., Gios, L., Gentilini, M. A., Mastellaro, M., Bartolotta, P., Nicolussi Giacomaz, L., Eccher, C., & Inchiostro, S. (2025). Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study). Frontiers in Clinical Diabetes and Healthcare. https://doi.org/10.3389/fcdhc.2025.1589548
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.